Obstacles to early treatment of idiopathic pulmonary fibrosis: current perspectives

References

• RaghuGCollardHREganJJAn official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and managementAm J Respir Crit Care Med2011183678882421471066
   PubMed Web of Science ®Google Scholar
• LynchDASverzellatiNTravisWDDiagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White PaperLancet Respir Med20186213815329154106
   PubMed Web of Science ®Google Scholar
• EspositoDBLanesSDonneyongMIdiopathic pulmonary fibrosis in United States automated claims. Incidence, prevalence, and algorithm validationAm J Respir Crit Care Med2015192101200120726241562
   PubMed Web of Science ®Google Scholar
• RaghuGChenSYHouQYehWSCollardHRIncidence and prevalence of idiopathic pulmonary fibrosis in US adults 18–64 years oldEur Respir J201648117918627126689
   PubMed Web of Science ®Google Scholar
• CollardHRRyersonCJCorteTJAcute exacerbation of idiopathic pulmonary fibrosis. An international working group reportAm J Respir Crit Care Med2016194326527527299520
   PubMed Web of Science ®Google Scholar
• RaghuGChenSYYehWSIdiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001–11Lancet Respir Med20142756657224875841
   PubMed Web of Science ®Google Scholar
• KingTEBehrJBrownKKBUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosisAm J Respir Crit Care Med20081771758117901413
   PubMed Web of Science ®Google Scholar
• RaghuGBehrJBrownKKTreatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trialAnn Intern Med2013158964164923648946
   PubMed Web of Science ®Google Scholar
• NothIAnstromKJCalvertSBA placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosisAm J Respir Crit Care Med20121861889522561965
   PubMed Web of Science ®Google Scholar
• CollardHRKingTEBartelsonBBVourlekisJSSchwarzMIBrownKKChanges in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosisAm J Respir Crit Care Med2003168553854212773325
   PubMed Web of Science ®Google Scholar
• du BoisRMWeyckerDAlberaCForced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important differenceAm J Respir Crit Care Med2011184121382138921940789
   PubMed Web of Science ®Google Scholar
• BehrJBonellaFBonnetRPosition paper: significance of the forced vital capacity in idiopathic pulmonary fibrosisPneumologie201569845545826227628
   PubMedGoogle Scholar
• KingTEBradfordWZCastro-BernardiniSA phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosisN Engl J Med2014370222083209224836312
   PubMed Web of Science ®Google Scholar
• RicheldiLdu BoisRMRaghuGEfficacy and safety of nintedanib in idiopathic pulmonary fibrosisN Engl J Med2014370222071208224836310
   PubMed Web of Science ®Google Scholar
• Karimi-ShahBAChowdhuryBAForced vital capacity in idiopathic pulmonary fibrosis – FDA review of pirfenidone and nintedanibN Engl J Med2015372131189119125806913
   PubMed Web of Science ®Google Scholar
• MaherTMMolina-MolinaMRussellAMUnmet needs in the treatment of idiopathic pulmonary fibrosis-insights from patient chart review in five European countriesBMC Pulm Med201717112428915874
   PubMed Web of Science ®Google Scholar
• MoodleyYCorteTRicheldiLKingTEDo all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro-con perspectiveRespirology201520338939425727967
   PubMed Web of Science ®Google Scholar
• KingCSNathanSDPOINT: should all patients with idiopathic pulmonary fibrosis, even those with more than moderate impairment, be treated with nintedanib or pirfenidone? YesChest2016150227327527292047
   PubMed Web of Science ®Google Scholar
• BrownKKCOUNTERPOINT: should all patients with idiopathic pulmonary fibrosis, even those with more than moderate impairment, be treated with nintedanib or pirfenidone? NoChest2016150227627827292046
   PubMed Web of Science ®Google Scholar
• FlahertyKRMumfordJAMurraySPrognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumoniaAm J Respir Crit Care Med2003168554354812773329
   PubMed Web of Science ®Google Scholar
• NathanSDReichmannWMMacaulayDYfYChange in forced vital capacity and clinical outcomes in newly diagnosed idiopathic pulmonary fibrosis patientsAm J Respir Crit Care Med2015191
   Web of Science ®Google Scholar
• ReichmannWMYuYFMacaulayDWuEQNathanSDChange in forced vital capacity and associated subsequent outcomes in patients with newly diagnosed idiopathic pulmonary fibrosisBMC Pulm Med201515116726714746
   PubMed Web of Science ®Google Scholar
• ArcaduAByrneSCPirinaPHartmanTEBartholmaiBJMouaTCorrelation of pulmonary function and usual interstitial pneumonia computed tomography patterns in idiopathic pulmonary fibrosisRespir Med201712915215728732823
   PubMed Web of Science ®Google Scholar
• SalisburyMLTolleLBXiaMPossible UIP pattern on high-resolution computed tomography is associated with better survival than definite UIP in IPF patientsRespir Med201713122923528947036
   PubMed Web of Science ®Google Scholar
• SumikawaHJohkohTColbyTVComputed tomography findings in pathological usual interstitial pneumonia – relationship to survivalAm J Respir Crit Care Med2008177443343917975197
   PubMed Web of Science ®Google Scholar
• de GiacomiFWhiteDCoxCWMouaTEvolution of diagnostic UIP computed tomography patterns in idiopathic pulmonary fibrosis: disease spectrum and implications for survivalRespir Med2018142535930170802
   PubMed Web of Science ®Google Scholar
• LeeHYLeeKSJeongYJHigh-resolution CT findings in fibrotic idiopathic interstitial pneumonias with little honeycombing: serial changes and prognostic implicationsAm J Roentgenol2012199598298923096169
   PubMed Web of Science ®Google Scholar
• DeandradeJConoscentiCFlahertyKTime from first imaging showing pulmonary fibrosis to diagnosis of idiopathic pulmonary fibrosis: data from the IPF-PRO registryChest20171524A445
   Web of Science ®Google Scholar
• LeyBRyersonCJVittinghoffEA multidimensional index and staging system for idiopathic pulmonary fibrosisAnn Intern Med20121561068469122586007
   PubMed Web of Science ®Google Scholar
• AlberaCCostabelUFaganEAEfficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung functionEur Respir J201648384385127471208
   PubMed Web of Science ®Google Scholar
• WellsAUForced vital capacity as a primary end point in idiopathic pulmonary fibrosis treatment trials: making a silk purse from a sow’s earThorax201368430931023019257
   PubMed Web of Science ®Google Scholar
• CollardHRBrownKKMartinezFJRaghuGRobertsRSAnstromKJStudy design implications of death and hospitalization as end points in idiopathic pulmonary fibrosisChest201414651256126225144827
   PubMed Web of Science ®Google Scholar
• AshSYVallejoDLLVillalbaJAQuantitative computed tomography analysis predicts outcomes in idiopathic pulmonary fibrosisAm J Respir Crit Care Med2016193A2603
   Google Scholar
• LedererDJArcasoySMWiltJSD’OvidioFSonettJRKawutSMSix-minute-walk distance predicts waiting list survival in idiopathic pulmonary fibrosisAm J Respir Crit Care Med2006174665966416778159
   PubMed Web of Science ®Google Scholar
• MorinoATakahashiHIshiaiSSix-minute walk distance is a surrogate parameter of physical activity in patients with idiopathic pulmonary fibrosisEur Respir J201342P1840
   Web of Science ®Google Scholar
• SwigrisJJFaircloughDPatient-reported outcomes in idiopathic pulmonary fibrosis researchChest2012142229129722871754
   PubMed Web of Science ®Google Scholar
• HunninghakeGWLynchDAGalvinJRRadiologic findings are strongly associated with a pathologic diagnosis of usual interstitial pneumoniaChest200312441215122314555549
   PubMed Web of Science ®Google Scholar
• FellCDMartinezFJLiuLXClinical predictors of a diagnosis of idiopathic pulmonary fibrosisAm J Respir Crit Care Med2010181883283720056903
   PubMed Web of Science ®Google Scholar
• MacdonaldSLRubensMBHansellDMNonspecific interstitial pneumonia and usual interstitial pneumonia: comparative appearances at and diagnostic accuracy of thin-section CTRadiology2001221360060511719652
   PubMed Web of Science ®Google Scholar
• HartmanTESwensenSJHansellDMNonspecific interstitial pneumonia: variable appearance at high-resolution chest CTRadiology2000217370170511110931
   PubMed Web of Science ®Google Scholar
• BrownellRMouaTHenryTSThe use of pretest probability increases the value of high-resolution CT in diagnosing usual interstitial pneumoniaThorax201772542442928082530
   PubMed Web of Science ®Google Scholar
• MorissetJJohannsonKAJonesKDIdentification of diagnostic criteria for chronic hypersensitivity pneumonitis. An International Modified Delphi SurveyAm J Respir Crit Care Med2018197810361044
   PubMed Web of Science ®Google Scholar
• MorellFVillarAMonteroMÁChronic hypersensitivity pneumonitis in patients diagnosed with idiopathic pulmonary fibrosis: a prospective case-cohort studyLancet Respir Med20131968569424429272
   PubMed Web of Science ®Google Scholar
• MouaTMaldonadoFDeckerPADanielsCERyuJHFrequency and implication of autoimmune serologies in idiopathic pulmonary fibrosisMayo Clin Proc201489331932624582190
   PubMed Web of Science ®Google Scholar
• LeeJSKimEJLynchKLPrevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosisRespir Med2013107224925523186614
   PubMed Web of Science ®Google Scholar
• FischerAAntoniouKMBrownKKAn official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune featuresEur Respir J201546497698726160873
   PubMed Web of Science ®Google Scholar
• OldhamJMAdegunsoyeAValenziECharacterisation of patients with interstitial pneumonia with autoimmune featuresEur Respir J20164761767177527103387
   PubMed Web of Science ®Google Scholar
• ChartrandSSwigrisJJStanchevLLeeJSBrownKKFischerAClinical features and natural history of interstitial pneumonia with autoimmune features: a single center experienceRespir Med201611915015427692137
   PubMed Web of Science ®Google Scholar
• RaghuGLynchDGodwinJDDiagnosis of idiopathic pulmonary fibrosis with high-resolution CT in patients with little or no radiological evidence of honeycombing: secondary analysis of a randomised, controlled trialLancet Respir Med20142427728424717624
   PubMed Web of Science ®Google Scholar
• HutchinsonJPFogartyAWMckeeverTMHubbardRBIn-hospital mortality after surgical lung biopsy for interstitial lung disease in the United States. 2000 to 2011Am J Respir Crit Care Med2016193101161116726646481
   PubMed Web of Science ®Google Scholar
• TomassettiSWellsAUCostabelUThe diagnostic role of cryobiopsy in the multidisciplinary diagnosis of idiopathic pulmonary fibrosisEur Respir J201342Suppl 57469s
   Google Scholar
• WuytsWAKolbMStowasserSStansenWHugginsJTRaghuGFirst data on efficacy and safety of nintedanib in patients with idiopathic pulmonary fibrosis and forced vital capacity of ≤50% of predicted valueLung2016194573974327377558
   PubMed Web of Science ®Google Scholar
• TzouvelekisANtoliosPKarampitsakosTSafety and efficacy of pirfenidone in severe idiopathic pulmonary fibrosis: a real-world observational studyPulm Pharmacol Ther201746485328843616
   PubMed Web of Science ®Google Scholar
• SakamotoSItohTMuramatsuYEfficacy of pirfenidone in patients with advanced-stage idiopathic pulmonary fibrosisIntern Med201352222495250124240787
   PubMed Web of Science ®Google Scholar
• TaguchiYEbinaMHashimotoSEfficacy of pirfenidone and disease severity of idiopathic pulmonary fibrosis: extended analysis of phase III trial in JapanRespir Investig2015536279287
   PubMedGoogle Scholar
• BiondiniDBalestroECocconcelliEEffect of 24-month Pirfenidone treatment on functional decline in Idiopathic Pulmonary Fibrosis (IPF) patients with rapid and slow disease progressionEur Respir J201750PA2966
   Web of Science ®Google Scholar
• KolbMRicheldiLBehrJNintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volumeThorax201772434034627672117
   PubMed Web of Science ®Google Scholar
• CostabelUInoueYRicheldiLEfficacy of nintedanib in idiopathic pulmonary fibrosis across prespecified subgroups in INPULSISAm J Respir Crit Care Med2016193217818526393389
   PubMed Web of Science ®Google Scholar
• RaghuGWellsAUNicholsonAGEffect of nintedanib in subgroups of idiopathic pulmonary fibrosis by diagnostic criteriaAm J Respir Crit Care Med20171951788527331880
   PubMed Web of Science ®Google Scholar
• KondohYTaniguchiHKataokaKLong-term effect of pulmonary rehabilitation under nintedanib treatment in idiopathic pulmonary fibrosis: methodology of the fitness studyAm J Respir Crit Care Med2017195A4280
   Web of Science ®Google Scholar
• CottinVNunesHBrilletPYCombined pulmonary fibrosis and emphysema: a distinct underrecognised entityEur Respir J200526458659316204587
   PubMed Web of Science ®Google Scholar
• CottinVNunesHMouthonLCombined pulmonary fibrosis and emphysema syndrome in connective tissue diseaseArthritis Rheum201163129530420936629
   PubMed Web of Science ®Google Scholar
• Fernández CasaresMFielliMCristaldoLZárateLNieves CapozziMRheumatoid arthritis and combined pulmonary fibrosis and emphysemaMedicina201575422522826339878
   PubMed Web of Science ®Google Scholar
• SoumagneTPana-KatataliHDeganoBDalphinJCCombined pulmonary fibrosis and emphysema in hypersensitivity pneumonitisBMJ Case Rep20152015bcr2015211560
   PubMedGoogle Scholar
• KitaguchiYFujimotoKHanaokaMHondaTHottaJHirayamaJPulmonary function impairment in patients with combined pulmonary fibrosis and emphysema with and without airflow obstructionInt J Chron Obstruct Pulmon Dis2014980581125114520
   PubMed Web of Science ®Google Scholar
• KitaguchiYFujimotoKHayashiRHanaokaMHondaTKuboKAnnual changes in pulmonary function in combined pulmonary fibrosis and emphysema: over a 5-year follow-upRespir Med2013107121986199223850272
   PubMed Web of Science ®Google Scholar
• CottinVHansellDMSverzellatiNEffect of emphysema extent on serial lung function in patients with idiopathic pulmonary fibrosisAm J Respir Crit Care Med201719691162117128657784
   PubMed Web of Science ®Google Scholar
• CrestaniBQuaresmaMKayeMStansenWStowasserSKreuterMLong-term nintedanib treatment in idiopathic pulmonary fibrosis (IPF): new data from INPULSIS-ONEur Respir J201750OA3402
   Web of Science ®Google Scholar
• FlahertyKRKolbMVancheriCTangWConoscentiCSRicheldiLStability or improvement in forced vital capacity with nintedanib in patients with idiopathic pulmonary fibrosisEur Respir J2018522170259329946007
   PubMed Web of Science ®Google Scholar
• LeyBSwigrisJDayBMPirfenidone reduces respiratory-related hospitalizations in idiopathic pulmonary fibrosisAm J Respir Crit Care Med2017196675676128471697
   PubMed Web of Science ®Google Scholar
• RicheldiLdu BoisRRaghuGEfficacy and safety of nintedanib in patients with idiopathic pulmonary fibrosis: results of two 52-week, Phase Iii, randomized, placebo-controlled trials (INPULSIS (TM))Am J Respir Crit Care Med20141928
   Google Scholar
• NathanSDAlberaCBradfordWZEffect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosisLancet Respir Med201751334127876247
   PubMed Web of Science ®Google Scholar
• VancheriCKreuterMRicheldiLNintedanib with add-on pirfenidone in idiopathic pulmonary fibrosis. Results of the INJOURNEY TrialAm J Respir Crit Care Med2018197335636328889759
   PubMed Web of Science ®Google Scholar
• FlahertyKRFellCDHugginsJTSafety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosisEur Respir J2018522180023029946005
   PubMed Web of Science ®Google Scholar
• LancasterLAlberaCBradfordWZSafety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trialsBMJ Open Respir Res201631e000105
   PubMed Web of Science ®Google Scholar
• CostabelUBendstrupECottinVPirfenidone in idiopathic pulmonary fibrosis: expert panel discussion on the management of drug-related adverse eventsAdv Ther201431437539124639005
   PubMed Web of Science ®Google Scholar
• ValeyreDAlberaCBradfordWZComprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosisRespirology201419574074724836849
   PubMed Web of Science ®Google Scholar
• CrestaniBKolbMWallaertBQuaresmaMStansenWRicheldiLLong-term efficacy of nintedanib is maintained in patients with idiopathic pulmonary fibrosis (IPF) irrespective of dose: subgroup analysis of INPULSIS-ONAm J Respir Crit Care Med2017195A5408
   Web of Science ®Google Scholar